Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM), ISIN INE048B01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
JAGSNPHARM last traded at ₹217.01 (+1.78%), with a 52-week range of ₹155.00 to ₹264.50 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 68.81%, FIIs 2.13%, DIIs 1.64%, mutual funds 0.00%.
EquiSense Score (ECS): 54/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.